MarxR.E., SawatariY., FortinM.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.J Oral Maxillo-fac Surg2005; 63(11): 1567–1575.
2.
BorromeoG.L., TsaoC.E., DarbyI.B.A review of the clinical implications of bisphosphonates in dentistry.Aust Dent J2011; 56(1): 2–9.
3.
RussellR.G., RogersM.J.Bisphosphonates: from the laboratory to the clinic and back again.Bone1999; 25(1): 97–106.
4.
RibattiD., NicoB., MangieriD.Neridronate inhibits angio-genesis in vitro and in vivo.Clin Rheumatol2007; 26(7): 1094–1098.
5.
YaromN., YahalomR., ShoshaniY.Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.Osteoporos Int2007; 18(10): 1363–1370.
6.
HillnerB.E., IngleJ.N., ChlebowskiR.T.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J Clin Oncol2003; 21(21): 4042–4057.
7.
OteriG., AllegraA., BellomoG.Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.Cytokine2008; 43(2): 103–104.
8.
MarxR.E.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.J Oral Maxillofac Surg2003; 61(9): 1115–1117.
9.
WangJ., GoodgerN.M., PogrelM.A.Osteonecrosis of the jaws associated with cancer chemotherapy.J Oral Maxillofac Surg2003; 61(9): 1104–1107.
10.
SedghizadehP.P., StanleyK., CaligiuriM.Oral bisphospho-nate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.J Am Dent Assoc2009; 140(1): 61–66.
11.
RuggieroS.L., DodsonT.B., AssaelL.A.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws — 2009 update.J Oral Maxillofac Surg2009; 67(5 Suppl): S2–S12.
12.
GuttaR., LouisP.J.Bisphosphonates and osteonecrosis of the jaws: science and rationale.Oral Surg Oral Med Oral Pathol Oral Radiol Endod2007; 104(2): 186–193.
13.
ChengA., DalyC.G., LoganR.M.Alveolar bone and the bis-phosphonates.Aust Dent J2009; 54(1 Suppl): S51–S61.
14.
HutchinsonM., O'RyanF., ChavezV.Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure.J Oral Maxillofac Surg2010; 68(9): 2232–2240.
15.
PatelS., ChoyeeS., UyanneJ.Non-exposed bisphospho-nate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.Oral Dis2012; 18(7): 625–632.
16.
NastroE., MusolinoC., AllegraA.Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.Acta Haematol2007; 117(3): 181–187.
17.
FreibergerJ.J., Padilla-BurgosR., ChhoeuA.H.Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.J Oral Maxillofac Surg2007; 65(7): 1321–1327.
18.
ShirotaT., NakamuraA., MatsuiY.Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case.Clin Oral Implants Res2009; 20(12): 1402–1408.
19.
FreibergerJ.J., Padilla-BurgosR., McGrawT.What is the role of hyperbaric oxygen in the management of bisphospho-nate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.J Oral Maxillofac Surg2012; 70(7): 1573–1583.
20.
TamimiW., AlaskarA., AlassiriM.Monoclonal gammopathy in a tertiary referral hospital.Clin Biochem2010; 43(9): 709–713.
21.
Van den WyngaertT., HuizingM.T., VermorkenJ.B.Bisphospho-nates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?Ann Oncol2006; 17(8): 1197–1204.
22.
FreibergerJ.J.Utility of hyperbaric oxygen in treatment of bis-phosphonate-related osteonecrosis of the jaws.J Oral Maxillo-fac Surg2009; 67(5): 96–106.
23.
AlonsK., KuijpersS., JongE.Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases.Oral Surg Oral Med Oral Pathol Oral Radiol Endod2009; 107(2): e1–e7.
24.
MeloM.D., ObeidG.Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.J Can Dent Assoc2005; 71(2): 111–113.
25.
KhamaisiM., RegevE., YaromN.Possible association between diabetes and bisphosphonate-related jaw osteonecrosis.J Clin Endocrinol Metab2007; 92(3): 1172–50117.
26.
SakamotoE., StratigosG.T.Bilateral cutaneous sinus tracts of dental etiology: report of case.J Oral Surg1973; 31(9): 701–704.
27.
KawaguchiS., KawaguchiY., KashimaM.Bilateral odon-togenous sinuses on the chin.Arch Dermatol1986; 122(11): 1240–1241.
TruongS.V., ChangL.C., BergerT.G.Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: a case report and review of the literature.J Am Acad Dermatol2010; 62(4): 672–676.
30.
WongchuensoontornC., LiebehenschelN., WagnerK.Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.J Oral Maxillofac Surg2009; 67(6): 1311–1316.
31.
RuggieroS.L., MehrotraB., RosenbergT.J.Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J Oral Maxillofac Surg2004; 62(5): 527–534.
32.
StantonD.C., BalasanianE.Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.J Oral Maxillofac Surg2009; 67(5): 943–950.
33.
OguraM., SaitohT., MiyamotoS.Surgical intervention of osteonecrosis of the jaws associated with bisphosphonate therapy: report of two cases.Asian J Oral Maxillofac Surg2010; 22(3): 148–153.
34.
MiglioratiC.A., SchubertM.M., PetersonD.E.Bisphospho-nate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.Cancer2005; 104(1): 83–93.
35.
StopeckA.T., LiptonA., BodyJ.J.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol2010; 28(35): 5132–5139.
